Dawn of Good Health


IN THE heart of UK, there is an In­dian who is mak­ing waves with his en­trepreneur­ship and phi­lan­thropy. We are talk­ing about Dr Nik Kotecha, who was awarded an OBE (Of­fi­cer of the Most Ex­cel­lent Or­der of the Bri­tish Em­pire) last sum­mer and is counted among the most dy­namic per­son­al­i­ties to have emerged in the phar­ma­ceu­ti­cal sec­tor in the UK, in re­cent years. This year, his com­pany is set to launch 12 new generic medicines in ar­eas ad­dress­ing the cen­tral ner­vous sys­tem, thy­roid, di­a­betes, on­col­ogy and pain re­lief. The OBE hon­our was not be­stowed on him for his work in the phar­ma­ceu­ti­cal sec­tor through his com­pany Morn­ing­side Phar­ma­ceu­ti­cals alone, but also for his phi­lan­throp­i­cal con­tri­bu­tion to so­ci­ety. With his wife Moni, Dr Kotecha runs the Kotecha fam­ily char­i­ta­ble trust called The Ran­dal Char­i­ta­ble Foun­da­tion. It aims to pro­vide ad­e­quate funds to save lives in the UK and in de­vel­op­ing coun­tries by pre­vent­ing poverty or re­liev­ing peo­ple of it. The foun­da­tion also works in the pub­lic health do­main by pro­vid­ing ap­pro­pri­ate med­i­cal care to save lives. Dr Kotecha has earned sev­eral no­table lau­rels for mak­ing qual­ity health­care an af­ford­able and ac­ces­si­ble re­al­ity across the globe. In 2012, he re­ceived the Queen’s Award for en­ter­prise and in­ter­na­tional trade. He also ac­com­pa­nied Prime Min­is­ter Theresa May on her visit to In­dia last year. May hailed Kotecha’s Morn­ing­side Phar­ma­ceu­ti­cals as “the best of Bri­tish”. She also re­ferred to his com­pany be­ing a great ex­am­ple of what the UK can of­fer the world af­ter Brexit. With so much be­ing said and done al­ready, it seems like Dr Kotecha would play a key role in R&D (Re­search and De­vel­op­ment) part­ner­ships be­tween In­dia and UK, apart from bring­ing shared op­por­tu­ni­ties for in­vest­ment with re­spect to In­dian phar­ma­ceu­ti­cal and clin­i­cal or­gan­i­sa­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.